𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Brain metastasis from prostate carcinoma : Antemortem recognition and outcome after treatment

✍ Scribed by Ian E. McCutcheon; David Y. Eng; Christopher J. Logothetis


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
104 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


BACKGROUND.

In patients with prostate carcinoma, brain metastasis has most commonly been reported in autopsy series. Symptomatic brain metastasis from prostate carcinoma has occasionally been detected.

METHODS.

The authors retrospectively studied a series of 38 patients with antemortem intracerebral metastasis found on review of 7994 patients treated over an 18-year period at the University of Texas M. D. Anderson Cancer Center.

RESULTS.

The mean time from diagnosis of prostate carcinoma to discovery of brain metastasis was 28 months, with a mean survival of 9.2 months after the discovery of the brain metastasis. The brain metastasis was treated only with whole brain irradiation in 29 patients, with craniotomy and irradiation in 8 patients, and with surgery alone in 1 patient. Small cell carcinomas and primary transitional cell carcinomas of the prostate were much more likely to produce brain metastasis than were adenocarcinomas. Also noted among the overall prostate carcinoma cohort was a second group of 16 patients with prostate carcinoma and brain metastasis that had developed from a second primary tumor, which in all was either lung carcinoma or melanoma.

CONCLUSIONS.

The occurrence of brain metastasis in prostate carcinoma patients is rare, usually signifies a late stage of the disease, and may in some patients be produced by a tandem extraprostatic tumor.


πŸ“œ SIMILAR VOLUMES


Quality of life and treatment outcomes :
✍ Cheryl L. Shrader-Bogen; Janice L. Kjellberg; Carol P. McPherson; Charles L. Mur πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 169 KB πŸ‘ 2 views

prostate carcinoma on overall QOL in the two treatment groups. The PCTO-Q of Minnesota Medical School, Minneapolis, assessed the patients' perceptions of the incidence and severity of specific changes Minnesota. in bowel, urinary, and sexual functions. The test-retest reliability of the PCTO-Q in a